Login / Signup

Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors.

Helena NorbergEllinor BergdahlKrister Lindmark
Published in: Cardiovascular therapeutics (2019)
Switching directly from target dose ACE inhibitors or ARBs to maximum-dose sacubitril-valsartan was safe and generally well tolerated.
Keyphrases
  • ejection fraction
  • end stage renal disease
  • newly diagnosed
  • clinical trial
  • prognostic factors
  • open label
  • angiotensin ii
  • patient reported outcomes
  • study protocol
  • double blind